The estimated Net Worth of Richard Alistair Stewart is at least $1.06 Million dollars as of 19 April 2024. Mr. Stewart owns over 22,500 units of Achieve Life Sciences stock worth over $261,084 and over the last 7 years he sold ACHV stock worth over $0. In addition, he makes $796,644 as Executive Chairman of the Board at Achieve Life Sciences.
Richard has made over 6 trades of the Achieve Life Sciences stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 22,500 units of ACHV stock worth $96,300 on 19 April 2024.
The largest trade he's ever made was exercising 22,500 units of Achieve Life Sciences stock on 19 April 2024 worth over $96,300. On average, Richard trades about 5,156 units every 112 days since 2017. As of 19 April 2024 he still owns at least 61,001 units of Achieve Life Sciences stock.
You can see the complete history of Mr. Stewart stock trades at the bottom of the page.
Richard Stewart serves as Executive Chairman of the Board of the Company. He has served as our Chairman, Chief Executive Officer and a director since the consummation of the Merger between OncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. in August 2017 (the “Merger”), and was Chairman and a director of Achieve Life Science, Inc., from its founding in May 2015, through the Merger. Mr. Stewart is also a founder and a director of Ricanto Limited, a pharmaceutical asset optimization company, since 2009. Mr. Stewart has been Chairman and Chief Executive Officer of Renown Pharma Limited, a central nervous system company focused on Parkinson’s disease, since 2016. Prior to Achieve, Mr. Stewart was Chairman and Chief Executive Officer of Huxley Pharmaceuticals, Inc., a single purpose central nervous system company, during 2009, prior to Huxley Pharmaceuticals, Inc.’s acquisition by BioMarin Pharmaceutical Inc. Mr. Stewart was Chief Executive Officer of Brabant Pharma Limited, a single purpose central nervous system company, from 2013 to 2014 prior to its acquisition by Zogenix Inc. He was a co-founder and Chief Executive Officer of Amarin Corporation plc, a central nervous system company focused on Parkinson’s disease and Huntington’s disease, from 2000 to 2007. Mr. Stewart was a co-founder and Chief Financial Officer, and later Chief Business Officer, of SkyePharma plc, a drug delivery company specializing in controlled release formulations, and held such positions from 1995 to 1998. Mr. Stewart holds a Bachelor of Science degree in Business Administration from the University of Bath. The determination was made that Mr. Stewart should serve on our Board of Directors based on our belief that it is of importance that the Board of Directors have the benefit of management’s perspective and, in particular, that of the Chief Executive Officer, as well as Mr. Stewart’s prior service on boards of directors, and extensive experience and innovations in the field of biotechnology.
As the Executive Chairman of the Board of Achieve Life Sciences, the total compensation of Richard Stewart at Achieve Life Sciences is $796,644. There are no executives at Achieve Life Sciences getting paid more.
Richard Stewart is 61, he's been the Executive Chairman of the Board of Achieve Life Sciences since 2020. There are 10 older and 6 younger executives at Achieve Life Sciences. The oldest executive at Achieve Life Sciences Inc. is Donald Joseph, 66, who is the Independent Director.
Richard's mailing address filed with the SEC is 22722 29TH DR SE, SUITE 100, BOTHELL, WA, 98021.
Over the last 7 years, insiders at Achieve Life Sciences have traded over $972,224 worth of Achieve Life Sciences stock and bought 70,500 units worth $224,475 . The most active insiders traders include Capital, Llc Armistice Capi..., Vaughn B Himes, and Jay M Moyes. On average, Achieve Life Sciences executives and independent directors trade stock every 65 days with the average trade being worth of $63,759. The most recent stock trade was executed by Jerry Wan on 19 April 2024, trading 5,625 units of ACHV stock currently worth $24,075.
achieve life sciences is a specialty pharmaceutical company committed to advancing cytisine as a smoking cessation aid to overcome the global nicotine addiction epidemic.
Achieve Life Sciences executives and other stock owners filed with the SEC include: